Distillate Capital Partners’s Horizon Therapeutics Public Limited Company Ordinary Shares HZNP Stock Holding History

Distillate Capital Partners’s Portfolio HZNP Stock Details HZNP Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q1	–	Sell	-153	Closed	-$17.4K	–	105
2022 Q4	$17.4K	Sell	153 -76,750	-100%	-$6.37M	1.61%	1
2022 Q3	$4.91M	Buy	76,903 +14,816	+24%	+$1.04M	0.66%	95
2022 Q2	$4.95M	Buy	62,087 +9,462	+18%	+$896K	0.71%	85
2022 Q1	$5.54M	Buy	52,625 +15,227	+41%	+$1.48M	0.79%	67
2021 Q4	$4.03M	Buy	37,398 +5,988	+19%	+$653K	0.68%	87
2021 Q3	$3.44M	Buy	31,410 +2,930	+10%	+$304K	0.92%	38
2021 Q2	$2.67M	Buy	+28,480	New	+$2.62M	0.74%	87

Other funds holding HZNP

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return

PCM

Pentwater Capital Management Naples, Florida $19.3B AUM 58.13% 1-Year Est. Return

HBK Investments Dallas, Texas $9.85B AUM 55.6% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

FCM

Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

DKCM

Davidson Kempner Capital Management New York $7.33B AUM 56.47% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Distillate Capital Partners's HZNP Position: Q1 2023 in Review

Distillate Capital Partners sold out of Horizon Therapeutics Public Limited Company Ordinary Shares (HZNP) in Q1 2023, closing a stake of 153 shares — an estimated $17.4K sold.

Distillate Capital Partners first reported a position in HZNP in Q2 2021 and held it in 7 quarters. The position peaked at $5.54M in Q1 2022. 553 funds tracked by Wall St. Rank hold HZNP as of Q1 2023.

Distillate Capital Partners reported no remaining Horizon Therapeutics Public Limited Company Ordinary Shares position as of Q1 2023 after selling out during the quarter.
Distillate Capital Partners sold 153 Horizon Therapeutics Public Limited Company Ordinary Shares shares in Q1 2023, an estimated $17.4K.
Distillate Capital Partners first reported a position in Horizon Therapeutics Public Limited Company Ordinary Shares in Q2 2021 and held it in 7 quarters.
Distillate Capital Partners's Horizon Therapeutics Public Limited Company Ordinary Shares position peaked at $5.54M in Q1 2022.
553 funds tracked by Wall St. Rank held Horizon Therapeutics Public Limited Company Ordinary Shares as of Q1 2023.

Based on Distillate Capital Partners's 13F filing for Q1 2023, filed 15 May 2023.